Vitamin E-based prodrug self-delivery for nanoformulated irinotecan with synergistic antitumor therapeutics

Small‐Molecule Prodrug Nanoassemblies: An Emerging Nanoplatform for Anticancer Drug Delivery

“…VES could interact with the ubiquinone (UbQ)‐binding site in mitochondrial respiratory chain Complex II to rapidly generate extra ROS (Figure 12 C 2 ). [ 108,239,240 ] The excessive ROS could synergize with the endogenous ROS to facilitate drug release via the positive‐feedback loop. In the intricate TME, the dual‐responsive prodrug nanoassemblies are more conducive to the on‐demand release of drugs.…”

Enzyme-responsive strategy as a prospective cue to construct intelligent biomaterials for disease diagnosis and therapy

“…An effective way to overcome these limitations is to develop carrier-free amphiphilic nanomedicine. 87 Yuan, Yi et al 88 developed a multifunctional polymer prodrug (P(OEGMA- co -CPT- co -G3-C12)) with both esterase sensitivity and cancer cell targeting properties. G3-C12 peptide could specifically bind to galectin-3 overexpressed at prostate cancer sites to increase its cancer cell targeting and selective cellular uptake performance.…”

“…Ling, Longbing et al 87 conjugated irinotecan (Ir) and vitamin E succinate through an esterification reaction to form anticancer agents, which could self-assemble into nanoparticles (VES-Ir NPs). After being internalized by cancer cells, Ir and VES were released in a pH/esterase-sensitive manner to exert a synergistic therapeutic effect.…”

Multicomponent carrier-free nanodrugs for cancer treatment

“…Otherwise, hydrophilic drugs and hydrophobic drugs are linked through acid-sensitive amide bonds, Schiff base bonds, and disulfide bonds, which have also been widely studied. 45,52–60…”